Akero Therapeutics (NASDAQ:AKRO) Shares Up 14.7%

Akero Therapeutics (NASDAQ:AKRO)’s stock price shot up 14.7% during trading on Monday . The stock traded as high as $23.09 and last traded at $22.75, 160,000 shares changed hands during trading. An increase of 38% from the average session volume of 116,198 shares. The stock had previously closed at $19.83.

Several brokerages recently commented on AKRO. Jefferies Financial Group began coverage on Akero Therapeutics in a report on Monday, July 15th. They set a “buy” rating and a $28.00 target price on the stock. Evercore ISI began coverage on Akero Therapeutics in a report on Monday, July 15th. They set an “outperform” rating and a $35.00 target price on the stock. Roth Capital began coverage on Akero Therapeutics in a report on Monday, July 15th. They set a “buy” rating and a $34.00 target price on the stock. Finally, JPMorgan Chase & Co. began coverage on Akero Therapeutics in a report on Monday, July 15th. They set an “overweight” rating and a $28.00 target price on the stock.

The business has a fifty day moving average of $24.29.

Akero Therapeutics (NASDAQ:AKRO) last announced its earnings results on Monday, August 12th. The company reported ($2.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($1.85). As a group, sell-side analysts expect that Akero Therapeutics will post -2.72 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of AKRO. Chicago Partners Investment Group LLC bought a new position in shares of Akero Therapeutics in the second quarter valued at $676,000. SG Americas Securities LLC bought a new position in shares of Akero Therapeutics in the second quarter valued at $192,000. Janus Henderson Group PLC bought a new position in shares of Akero Therapeutics in the second quarter valued at $14,578,000. Candriam Luxembourg S.C.A. bought a new position in shares of Akero Therapeutics in the second quarter valued at $381,000. Finally, Monashee Investment Management LLC bought a new position in shares of Akero Therapeutics in the second quarter valued at $2,107,000. 37.34% of the stock is currently owned by institutional investors.

About Akero Therapeutics (NASDAQ:AKRO)

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Further Reading: Beta

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.